Annovis Bio to Host Corporate Update Webinar on Clinical Programs and Milestones

Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing buntanetap for Alzheimer's and Parkinson's diseases, will host a corporate update webinar on Sept. 2, 2026, at 4 p.m. EDT. Founder, President and CEO Maria Maccecchini, Ph.D., will discuss recent progress, ongoing clinical programs, and upcoming milestones, including the fully enrolled pivotal Phase 3 AD trial, with top-line data and regulatory submissions expected in 2027.

The announcement underscores the company's commitment to advancing its pipeline. Annovis plans to begin enrolling patients in an AD open-label study in October 2026 to generate long-term safety data, while its PD open-label study is already underway. Additionally, discussions are ongoing regarding the initiation of a Parkinson's disease dementia program.

This webinar is a key opportunity for investors and stakeholders to gain insights into the company's strategic direction. The live Q&A session will allow participants to engage directly with management. Annovis aims to address the underlying causes of neurodegeneration by inhibiting the translation of multiple neurotoxic proteins, including APP, amyloid beta, tau, alpha-synuclein, and TDP-43.

The company's lead drug candidate, buntanetap (formerly posiphen), is an investigational once-daily oral therapy designed to halt disease progression and improve cognitive and motor functions. With the Phase 3 AD trial fully enrolled, the upcoming data readout could be a significant catalyst for the company.

Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company's mission is to improve the lives of patients by targeting the root causes of these debilitating conditions.

For more information about Annovis Bio and its clinical programs, visit annovisbio.com. To view the full press release, visit https://ibn.fm/mls3F.